PHARMASSISTANCE
ActiveSummary
PHARMASSISTANCE has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€368,433) and a net result of -€1,501. Equity remains stable across the filed financial years (±0.2% per year). Its solvency ranks better than 5% of 10,739 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Directors
Directors
under verification, last change in 2023
This board is reconstructed from a single act (23452013). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
Board 2
BOECKX Jozef Frans Dimphna
CurrentDirector (not named in the articles)
VANHOUCKE Kristien Maria Yvonne
CurrentDirector (not named in the articles)
Day-to-day management 1
Mediphar Invest
CurrentManaging director · since 11-12-2023 · Public limited company · permanent representative: BOECKX Jozef Frans Dimphna
Permanent representatives 1
BOECKX Jozef Frans Dimphna
CurrentPermanent representative · since 11-12-2023 · for Mediphar Invest
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
2 of this company's 3 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
3 people since 2023, 3 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| BOECKX Jozef Frans Dimphna |
|
| VANHOUCKE Kristien Maria Yvonne |
|
| Mediphar Invest |
|
Owners and capital
Capital and shareholders
Capital over the years
- 11-12-2023 Capital stated in the deed · €105,000 · 100 shares